Combination treatment with anti-sclerostin antibody and ZA is superior in preventing bone loss in the 5TGM1 murine model of myeloma. (A) Schematic describing the study design for investigations of bone loss in 5TGM1-eGFP–bearing mice treated with both anti-sclerostin antibody and ZA. (B) Examples of 3D microCT reconstructions of distal femora from each treatment group. (C) Dot plots of BV/TV trabecular thickness and number and cortical bone thickness in femora for each treatment group (n = 8 per group). Data are mean ± 1 SEM; *P < .05; **P < .01; ***P < .001; ****P < .0001. (D) Dot plot of L4 vertebra BV/TV for each treatment group (data are mean ± 1 SEM; **P < .01; ***P < .001; ****P < .0001; #P < .05 [Student t test]). (E) Structural parameters from microCT scans of L4 vertebrae (n = 8 per group). Data are mean ± 1 SEM; ^aP < .001; ^bP < .01; ^dP < .05 compared with naive plus control mice; ^eP < .001; ^fP < .05 compared with 5TGM1 plus control mice; ^gP < .001 compared with 5TGM1 plus ZA; ^hP < .001 compared with 5TGM1 plus anti-sclerostin antibody. (F) Dot plot of maximum load from L4 vertebra for each treatment group (n = 8 per group). Data are mean ± 1 SEM; **P < .01; ***P < .001; #P < .05 [Student t test].